Výsledky vyhledávání - "Degenfeld-Schonburg L"

Akademický článek

Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V ⁺ systemic mastocytosis: a preclinical study.

Autor: Degenfeld-Schonburg L; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Austria., Gamperl S; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Austria., Stefanzl G; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Schruef AK; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Austria., Sadovnik I; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Bauer K; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Smiljkovic D; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Eisenwort G; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Peter B; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Greiner G; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria.; Ihr Labor, Medical Diagnostic Laboratories Vienna, Austria., Hadzijusufovic E; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria.; Department/Hospital for Companion Animals and Horses, University Hospital for Small Animals, Internal Medicine Small Animals, University of Veterinary Medicine Vienna Austria., Schwaab J; Department of Hematology and Oncology, University Medical Centre Mannheim and Medical Faculty Mannheim, Heidelberg University Germany., Sperr WR; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Hoermann G; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria.; MLL Munich Leukemia Laboratory Munich, Germany., Kopanja S; Department of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology, Allergy and Endocrinology, Medical University of Vienna Austria., Szépfalusi Z; Department of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology, Allergy and Endocrinology, Medical University of Vienna Austria., Hoetzenecker K; Department of Surgery, Division of Thoracic Surgery, Medical University of Vienna Austria., Jaksch P; Department of Surgery, Division of Thoracic Surgery, Medical University of Vienna Austria., Reiter A; Department of Hematology and Oncology, University Medical Centre Mannheim and Medical Faculty Mannheim, Heidelberg University Germany., Arock M; Department of Hematological Biology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University (UPMC) Paris, France., Valent P; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria.

Publikováno v: American journal of cancer research [Am J Cancer Res] 2023 Feb 15; Vol. 13 (2), pp. 355-378. Date of Electronic Publication: 2023 Feb 15 (Print Publication: 2023).

Zobrazit plný text záznamu

Akademický článek

Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph ⁺ Chronic Myeloid Leukemia.

Autor: Sadovnik I; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria., Ivanov D; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria., Smiljkovic D; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria., Stefanzl G; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria., Degenfeld-Schonburg L; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria., Herndlhofer S; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria., Eisenwort G; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.; Third Medical Department for Hematology and Oncology, Hanusch Hospital Vienna, 1140 Vienna, Austria., Hauswirth AW; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria., Sliwa T; Third Medical Department for Hematology and Oncology, Hanusch Hospital Vienna, 1140 Vienna, Austria., Keil F; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.; Third Medical Department for Hematology and Oncology, Hanusch Hospital Vienna, 1140 Vienna, Austria., Sperr WR; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria., Valent P; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.

Publikováno v: Cells [Cells] 2022 Dec 20; Vol. 12 (1). Date of Electronic Publication: 2022 Dec 20.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 ^T315I -compound mutations.

Autor: Gleixner KV; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Filik Y; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Berger D; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria., Schewzik C; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria., Stefanzl G; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Sadovnik I; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Degenfeld-Schonburg L; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria., Eisenwort G; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Schneeweiss-Gleixner M; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria.; Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna Austria., Byrgazov K; Children's Cancer Research Institute (CCRI) Vienna, Austria., Sperr WR; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Mayer J; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University Brno, Czech Republic.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno Czech Republic., Lion T; Children's Cancer Research Institute (CCRI) Vienna, Austria., Valent P; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria.

Publikováno v: American journal of cancer research [Am J Cancer Res] 2021 Sep 15; Vol. 11 (9), pp. 4470-4484. Date of Electronic Publication: 2021 Sep 15 (Print Publication: 2021).

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání